TY - JOUR
T1 - A case of small-cell lung carcinoma treated with carboplatin plus etoposide combination chemotherapy under hemodialysis
AU - Yasuda, Rinako
AU - Naoki, Katsuhiko
AU - Okamoto, Hiroaki
AU - Tsujimura, Shuko
AU - Fujii, Tomoki
AU - Hida, Naoya
AU - Kunikane, Hiroshi
AU - Soejima, Kenzo
AU - Ishizaka, Akitoshi
AU - Watanabe, Koshiro
PY - 2009/9
Y1 - 2009/9
N2 - In recent years there are many patients who undergo hemodialysis because of chronic renal failure. Along with that, cases where lung cancer is discovered in patients undergoing hemodialysis are increasing. However, a standard chemotherapy for lung cancer patients undergoing maintenance hemodialysis has not yet been established with this in mind, we conducted chemotherapy using carboplatin 300mg/m 2(day 1) plus etoposide 50mg/m 2(day 1, 3) in a patient with limited-stage small cell lung cancer, who was also receiving maintenance hemodialysis. We investigated 16 small-cell lung cancer cases reported since 2000 in Japan that had been treated with carboplatin and etoposide under hemodialysis for chronic renal failure. Reviewing these cases, it is suggested that most effective schedule would be to use a higher dose in the first course followed by dose reduction as necessary for further courses. Although we were able to treat this case safely, the response was limited to an SD(stable disease). Further study is needed to determine the optimal dosage of each drug for small-cell lung cancer with maintenance hemodialysis.
AB - In recent years there are many patients who undergo hemodialysis because of chronic renal failure. Along with that, cases where lung cancer is discovered in patients undergoing hemodialysis are increasing. However, a standard chemotherapy for lung cancer patients undergoing maintenance hemodialysis has not yet been established with this in mind, we conducted chemotherapy using carboplatin 300mg/m 2(day 1) plus etoposide 50mg/m 2(day 1, 3) in a patient with limited-stage small cell lung cancer, who was also receiving maintenance hemodialysis. We investigated 16 small-cell lung cancer cases reported since 2000 in Japan that had been treated with carboplatin and etoposide under hemodialysis for chronic renal failure. Reviewing these cases, it is suggested that most effective schedule would be to use a higher dose in the first course followed by dose reduction as necessary for further courses. Although we were able to treat this case safely, the response was limited to an SD(stable disease). Further study is needed to determine the optimal dosage of each drug for small-cell lung cancer with maintenance hemodialysis.
KW - Combined chemotherapy
KW - Hemodialysis
KW - Small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=70350062205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350062205&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:70350062205
SN - 0452-3458
VL - 57
SP - 963
EP - 968
JO - Respiration and Circulation
JF - Respiration and Circulation
IS - 9
ER -
